PCR, polymerase chain reaction; CIN 1, 2, or 3, cervical intraepithelial neoplasia (1 = low grade, 2, 3 = high grade); SHARP, solution hybridization assay for PCR products; and ICRF, Imperial
the polymerase chain reaction (PCR) as a practicable alternative.
We used a protocol with deliberately reduced sensitivity to avoid problems with contamination and inhibitors (1). In a pilot study involving 105 women referred to a colposcopy clinic because of smears with repeated mild or borderline results, we used type-specific PCR to identify HPV16, 18, 31, and 33 DNA in cervical scrapes, and accurately predicted 14 of the 22 women who showed histological evidence of high-grade disease (3). Type-specific PCR is labor intensive, and confirmation of the identity of type-specific PCR products by gel electrophoresis is time consuming. The technique would have only limited value in a cytological screening program where large numbers of routine cervical samples have to be examined at a reasonable cost. We show here that a BIOMEK 1000 laboratory workstation (Beckman Instruments, High Wycombe, UK) could be used to process a standardized commercial system, the SHARP (Solution Hybridization Assay for PCR Products) SignaV'1 (Digene Diagnostics), for the semiautomated detection of HPV DNA of both high-and low-risk types. who also advised us on the experimental cytological abnormalities or risk of cervical disease was procedures. The detection system is based on liquid-phase reported previously (5, 6). Our type-specific PCR results hybridization of an RNA probe to a biotinylated PCR prodfurther suggest that the estimation of HPV DNA in ceruct, capture of the RNA-DNA hybrids onto streptavidinvical smears against known standards can correlate with coated plates, and subsequent detection and quantification clinical disease (1, 2). The approach we describe, however, of captured hybrids with an alkaline phosphatase-labeled can be used for routine purposes only if it can be autoantibody specific for RNA-DNA hybrids. For the semimated. Such automation might take the form of multiautomated procedure we used consensus PCR primers (4) by type-specific PCR (small amounts of the high-risk HPV types tested for) but were positive with the SHARP high-risk probe mix B. Four of these were positive for HPV18.
Materials and Methods

A BIOMEK 1000
In general, the consensus primers used in SHARP detects HPV18 DNA with greater sensitivity than HPV DNA of types 16, 31, or 33; this may account for the positive identification of some specimens estimated to have only a small amount of HPV18 by typespecific PCR. The remaining four specimens might contain one of the five additional high-risk HPV types detectable by the SHARP procedure. Only two of the eight women had abnormalities that were evident by colposcopy and had been biopsied. One was histologically normal and the other was CIN 2.
In the diagnosis of some infectious agents by PCR, detection of a single copy of the DNA may have profound implications (e.g., human immunodeficiency virus, congenital rubella). In contrast, the copy number of HPV DNAs that we have found to broadly distinguish histologically confirmed high-grade from low-grade cervical lesions equates to -100 000 copies per smear. The PCR protocol we used is therefore one of intentionally low sensitivity, and contamination leading to erroneous results has not been a problem in our laboratory. Nevertheless, we do take the precaution of preparing PCR reagents in a clean environment in sets (one set is used for each PCR run) and all manipulations by the BI-OMEK operate inside a safety cabinet. The consensus primers and the amplified region are also dedicated for use only in this project. To monitor for PCR inhibitors, we add to randomly selected samples plasmid DNA containing known HPV sequences at concentrations corresponding to small amounts of DNA amplified by typespecific PCR. At the high sample dilutions we use inhibitors are not a problem. The time it takes to dispense one reagent to one 96-well tray varies from 2 to 5 mm. Although this time it well within the capability of a manual operator using s multichannel pipette, the robot has the important advantage of eliminating operator error, which can readil3 occur in any highly repetitive procedure. With minoi adjustments to suit individual needs, the Digene system is simple to perform, but detection of the amplified DN requires a total incubation time of at least 4-5 h. The BIOMEK robotic arm would therefore be obligatory if a fully automated system were required. Cytological surveillance has proved to be an effective measure in reducing the incidence of cervical cancer and precancer in recent years. However, it is evident that some women who present with mild cytological abnormalities have high-grade lesions, and that these women, even with an ideal cytological surveillance program, can be lost to follow-up. There is, therefore, a need for more sensitive and specific diagnostic tests that can detect tumor formation at an early stage, and the test for high-risk HPV DNA is an obvious candidate.
We have shown that a simple, fully standardized PCR method based on the use of commercially available components produces objective data that correlate with clinical disease. The test can be carried out with little input labor and minimal technical expertise by a robotic system operating from preprogrammed subroutines. From data from our current semiautomated protocol of 184 specimens per run, we estimate that the unit cost of the BIOMEK/SHARP system would be comparable to cervical cytology (manuscript in preparation).
This cost would be significantly reduced by full automation and increased throughput and should not represent a major financial burden when used as an adjunct to cytology in the screening program. Since the SHARP signal system is adaptable to identification of any PCR product for which a specific probe is available, the diagnostic approach reported here could be further exploited for automated identification of any normal or mutated nucleic acid cancer markers in other cancer screening programs.
